8-K
filed October 3, 2022, 7:59 PM ET
ticker BHVN
CIK 0001935979
other material
confidence high
sentiment neutral
materiality 0.90
Biohaven Ltd. completes spin-off from RemainCo, appoints CFO and board
Biohaven Ltd.
- Spin-off effective Oct 3, 2022; shareholders received 1 Biohaven share per 2 RemainCo shares; 35,832,557 shares issued.
- Matthew Buten appointed CFO effective Sept 28, 2022.
- Board of directors named: Class I (Antonijevic, Heffernan, Hugin), Class II (Bailey, Childs, Gregory), Class III (Coric, Mehta).
- Adopted 2022 Equity Incentive Plan, Employee Share Purchase Plan, and Legacy Award Settlement Plan.
- Entered transition services, US distribution (Nurtec ODT) and outsourcing agreements with RemainCo and Pfizer.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
John Childs was appointed as Director at Biohaven Ltd..
- Action
- appointed
- Role
- Director
Exact text from the filing
Designated as Class II directors, with initial terms expiring at the 2024 annual meeting of Biohaven shareholders: • Gregory Bailey • John Childs
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Gregory Bailey was appointed as Director at Biohaven Ltd..
- Action
- appointed
- Role
- Director
Exact text from the filing
Designated as Class II directors, with initial terms expiring at the 2024 annual meeting of Biohaven shareholders: • Gregory Bailey
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Kishan Mehta was appointed as Director at Biohaven Ltd..
- Action
- appointed
- Role
- Director
Exact text from the filing
Designated as Class III directors, with initial terms expiring at the 2025 annual meeting of Biohaven shareholders: • Vladimir Coric • Kishan Mehta
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Matthew Buten was appointed as Chief Financial Officer at Biohaven Ltd..
- Action
- appointed
- Role
- Chief Financial Officer
Exact text from the filing
On September 28, 2022, the Company appointed Matthew Buten as Chief Financial Officer.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Vladimir Coric was appointed as Director at Biohaven Ltd..
- Action
- appointed
- Role
- Director
Exact text from the filing
Designated as Class III directors, with initial terms expiring at the 2025 annual meeting of Biohaven shareholders: • Vladimir Coric • Kishan Mehta
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Robert Hugin was appointed as Director at Biohaven Ltd..
- Action
- appointed
- Role
- Director
Exact text from the filing
Designated as Class I directors, with initial terms expiring at the 2023 annual meeting of Biohaven shareholders: • Irina Antonijevic • Michael T. Heffernan • Robert Hugin
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Michael T. Heffernan was appointed as Director at Biohaven Ltd..
- Action
- appointed
- Role
- Director
Exact text from the filing
Designated as Class I directors, with initial terms expiring at the 2023 annual meeting of Biohaven shareholders: • Irina Antonijevic • Michael T. Heffernan
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Julia Gregory was appointed as Director at Biohaven Ltd..
- Action
- appointed
- Role
- Director
Exact text from the filing
Designated as Class II directors, with initial terms expiring at the 2024 annual meeting of Biohaven shareholders: • Gregory Bailey • John Childs • Julia Gregory
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Irina Antonijevic was appointed as Director at Biohaven Ltd..
- Action
- appointed
- Role
- Director
Exact text from the filing
The following persons were appointed as directors of Biohaven on September 28, 2022: Designated as Class I directors, with initial terms expiring at the 2023 annual meeting of Biohaven shareholders: • Irina Antonijevic
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.